title: Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles.
abstract: Pharmacological agents suggested for infarct size limitation have serious side effects when used at cardioprotective doses which hinders their translation into clinical practice. The solution to the problem might be direct delivery of cardioprotective drugs into ischemic-reperfused myocardium. In this study, we explored the potential of silica nanoparticles for passive delivery of adenosine, a prototype cardioprotective agent, into ischemic-reperfused heart tissue. In addition, the biodegradation of silica nanoparticles was studied both in vitro and in vivo. Immobilization of adenosine on the surface of silica nanoparticles resulted in enhancement of adenosine-mediated infarct size limitation in the rat model. Furthermore, the hypotensive effect of adenosine was attenuated after its adsorption on silica nanoparticles. We conclude that silica nanoparticles are biocompatible materials that might potentially be used as carriers for heart-targeted drug delivery.
authors.affiliation: Institute of Experimental Medicine, VA Almazov Federal Heart, Blood and Endocrinology Center, St Petersburg, Russian Federation. galagoudza@mail.ru
authors.forename: Michael
authors.initials: M
authors.lastname: Galagudza
authors.forename: Dmitry
authors.initials: D
authors.lastname: Korolev
authors.forename: Viktor
authors.initials: V
authors.lastname: Postnov
authors.forename: Elena
authors.initials: E
authors.lastname: Naumisheva
authors.forename: Yulia
authors.initials: Y
authors.lastname: Grigorova
authors.forename: Ivan
authors.initials: I
authors.lastname: Uskov
authors.forename: Eugene
authors.initials: E
authors.lastname: Shlyakhto
mesh_terms: D000241:Adenosine / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004337:Drug Carriers / Q000008:administration & dosage; D016503:Drug Delivery Systems; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D050997:Nanomedicine; D053758:Nanoparticles / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D012822:Silicon Dioxide; D014018:Tissue Distribution
chemical_list: D002316:Cardiotonic Agents; D004337:Drug Carriers; D012822:Silicon Dioxide; D000241:Adenosine